(R)-5-溴甲基-2-吡咯烷酮 | 98612-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (R)-5-溴甲基-2-吡咯烷酮
• 中文别名: (5R)-5-溴甲基-2-吡咯烷二酮；(R)-5-(溴甲基)-2-吡咯烷酮
• 英文名称: (R)-5-(bromomethyl)pyrrolidin-2-one
• 英文别名: (5R)-5-(bromomethyl)pyrrolidin-2-one；(R)-5-(bromomethyl)-2-pyrrolidinone；(R)-5-Bromomethyl-2-pyrrolidinone
• CAS: 98612-60-3
• 化学式: C₅H₈BrNO
• 分子量: 178.029
• InChiKey: QFOSFXPTXNRRMF-SCSAIBSYSA-N

物化性质

• 熔点：
  76-80°C
• 沸点：
  336.1±15.0 °C(Predicted)
• 密度：
  1.541±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• WGK Germany：
  3
• 危险品运输编号：
  UN 2811
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317,H319

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : (R)-5-(Bromomethyl)-2-pyrrolidinone
CAS-No. : 98612-60-3

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Eye irritation (Category 2)
Skin sensitization (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes. May cause sensitization by skin contact.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
May cause an allergic skin reaction.
Causes serious eye irritation.
Precautionary statement(s)
Wear protective gloves.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36 Irritating to eyes.
R43 May cause sensitization by skin contact.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C5H8BrNO
Molecular Weight : 178,03 g/mol
Component Concentration
(R)-5-(Bromomethyl)-2-pyrrolidinone
CAS-No. 98612-60-3 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use
respirators and components tested and approved under appropriate government standards such as
NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 76 - 80 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density 6,15 - (Air = 1.0)
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,489
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause sensitization by skin contact.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-5-溴甲基-2-吡咯烷酮 在 偶氮二异丁腈 、 三正丁基氢锡 、 sodium hydride 、 copper(l) chloride 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 (-)-Bok 1
  参考文献：
  名称：

  Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogs. N-[4-tert-amino-2-butynyl]-5-methyl-2-pyrrolidones

  摘要：

  The enantiomers of three 5-methyl-2-pyrrolidone analogues of the muscarinic agent oxotremorine (1) were synthesized. The pyrrolidine derivative (R)-13 was an antagonist to carbachol in the guinea pig ileum and also showed central and peripheral antimuscarinic activity in vivo. It was more potent and more selective than atropine in antagonizing the central effects of 1. The dimethylamino analogue (R)-14 and the trimethylammonium salt (R)-15 were potent agonists in the guinea pig ileum. (R)-14 showed both central muscarinic (hypothermia) and central antimuscarinic activity (antagonism of oxotremorine-induced tremor) in vivo. The R enantiomers of 13-15 were considerably more potent than the S enantiomers in vivo and in vitro irrespective of whether agonist or antagonist activity was measured. From a comparison of the contribution of the methyl group at the chiral center to the overall affinities, it is suggested that agonists and antagonists in this series bind in an essentially identical manner to the muscarinic receptor.

  DOI：

  10.1021/jm00150a004
• 作为产物：
  描述：

  D-焦谷氨酸 在 sodium tetrahydroborate 、 氯化亚砜 、 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 69.5h， 生成 (R)-5-溴甲基-2-吡咯烷酮
  参考文献：
  名称：

  Cytochalasans的合成方法Part9。导致细胞松弛素所有结构类型的通用概念†

  摘要：

  从D-谷氨酸（5）开始，通过17（方案1和2）合成了双环化合物4a和4b。用LiCuPh 2导致4g和4h的反应不成功。但治疗N-保护的模型的内酰胺19，21，和22与Li 2的Cu（CN）PH 2，得到氨基酮24，26，和27，分别为（方案3）。所需化合物23从得到20转换未受保护内酰胺的28，31，和32，得到苯基衍生物34以优良产率。酯35被转化为α-氨基-γ-氧代酸衍生物36。这种转化打开了对这类化合物的新颖途径。

  DOI：

  10.1002/hlca.19900730113

文献信息

• FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
  申请人：Novartis AG

  公开号：US20180312507A1

  公开（公告）日：2018-11-01

  The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

  这项发明提供了如下所述的化合物的化学式(I)，以及药用盐、含有这些化合物的药物组合物，以及使用这些化合物、盐和组合物治疗病毒感染，特别是由乙型肝炎病毒引起的感染，并减少与HBV相关的严重病情发生的方法。
• Highly Convergent Total Synthesis and Assignment of Absolute Configuration of Majusculamide D, a Potent and Selective Cytotoxic Metabolite from <i>Moorea sp.</i>
  作者：Eduardo J. E. Caro-Diaz、Frederick A. Valeriote、William H. Gerwick

  DOI：10.1021/acs.orglett.8b04050

  日期：2019.2.1

  The total synthesis of majusculamide D (MJS-D) is described, a lipopentapeptide originally isolated from Lyngbya majuscula and reisolated from a Moorea sp. MJS-D possesses selective and potent cancer cell toxicity. A scalable and convergent strategy with a minimal number of purifications produced significant quantities of MJM-D for in vivo evaluations. The absolute configuration of the 1,3-dimethyl-octanamide

  描述了Majusculamide D（MJS-D）的总合成，一种脂五肽最初从Lyngbya majuscula分离出来，然后从Moorea sp。中分离出来。MJS-D具有选择性和有效的癌细胞毒性。具有最少纯化次数的可扩展且收敛的策略可产生大量MJM-D用于体内评估。通过经由ZACA化学合成该片段来确定1，3-二甲基-辛酰胺基序的绝对构型。
• [EN] AZALACTAM COMPOUNDS AS HPK1 INHIBITORS<br/>[FR] COMPOSÉS D'AZALACTAME UTILISÉ EN TANT QU'INHIBITEURS DE HPK1
  申请人：PFIZER

  公开号：WO2021220185A1

  公开（公告）日：2021-11-04

  This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

  这项发明涉及一般式（I）的化合物及其药用盐，其中R1、R2、R3a、R3b和R4如本文所定义，涉及包含这些化合物和盐的药物组合物，以及使用这些化合物、盐和组合物治疗异常细胞生长，包括癌症的方法。
• Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1
  作者：Daniel P. Mould、Ulf Bremberg、Allan M. Jordan、Matthis Geitmann、Alba Maiques-Diaz、Alison E. McGonagle、Helen F. Small、Tim C.P. Somervaille、Donald Ogilvie

  DOI：10.1016/j.bmcl.2017.05.018

  日期：2017.7

  A series of reversible inhibitors of lysine specific demethylase 1 (LSD1) with a 5-hydroxypyrazole scaffold have been developed from compound 7, which was identified from the patent literature. Surface plasmon resonance (SPR) and biochemical analysis showed it to be a reversible LSD1 inhibitor with an IC50 value of 0.23 µM. Optimisation of this compound by rational design afforded compounds with Kd

  已经从化合物7开发了具有5-羟基吡唑支架的一系列赖氨酸特异性脱甲基酶1（LSD1）的可逆抑制剂，其已从专利文献中鉴定。表面等离子体共振（SPR）和生化分析表明，它是可逆的LSD1抑制剂，IC 50值为0.23 µM。通过合理设计优化该化合物，可得到K d <10 nM的化合物。在人类THP-1细胞中，发现这些化合物上调替代细胞生物标志物CD86的表达。发现化合物11p在小鼠中具有中等的口服生物利用度，表明其可用作体内工具化合物的潜力。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012154777A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和用于治疗丙型肝炎病毒（HCV）感染的方法，其化学式如下（I）。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。